Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Rosa Cruz is getting used to a new body — and a new life. Cancer shifted the way she communicates with her loved ones, navigates the world and approaches her passions in life. But the 32-year-old San ...

The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...

Please provide your email address to receive an email when new articles are posted on . Inherited mutations in SMARCAL1 are significantly linked to osteosarcoma risk, an analysis of DNA damage repair ...

75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf ...

Pediatric bone and soft tissue sarcomas, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma, represent devastating ...